Experts advocate for using AKT inhibitors in the early, hormone-sensitive setting for PTEN-deficient prostate cancer. The rationale is that early-stage disease is more dependent on the AKT pathway. In later, castrate-resistant stages, the cancer develops other resistance mechanisms and alterations, diminishing the potential impact of a targeted AKT inhibitor.

A potential unstated argument for approving capivasertib, despite its borderline data, was the fear that a rejection would kill the entire field of AKT inhibitors. This suggests that broader strategic concerns about fostering innovation can sometimes influence regulatory recommendations more than a single drug's specific risk-benefit profile.

The CAPITELLO-281 trial showed the AKT inhibitor capivasertib delayed disease progression in PTEN-deficient prostate cancer. However, without a demonstrated overall survival benefit yet, its path to becoming a new standard of care is uncertain. This highlights the growing debate over whether delaying progression is a sufficient endpoint to justify added toxicities when survival isn't improved.

The CAPItello-281 trial shows the benefit of the AKT inhibitor capivasertib is on a spectrum. Patients with 100% PTEN protein loss by IHC derive a much greater benefit than those with partial loss, suggesting a quantitative biomarker may optimize patient selection.

The drug is already approved in breast cancer with a stronger PFS benefit (HR 0.5-0.6) and lower toxicity. Its weaker data in prostate cancer (HR 0.81, 60% grade 3 toxicity) demonstrates that the same drug faces a much higher regulatory bar when the benefit-risk calculation is less favorable in a new disease context.

Despite some positive clinical trial data for AKT inhibitors in prostate cancer, expert opinion suggests this class of drugs is unlikely to see the light of day in routine clinical practice. Skepticism remains about their overall impact, with a feeling that they do not represent a new, meaningful chapter for treatment.

Using capivasertib in the hormone-sensitive setting is preferred because the cancer is more likely dependent on the AKT pathway for growth. In later, castration-resistant stages, additional genetic alterations can emerge, creating redundant growth signals and potentially diminishing the inhibitor's efficacy.

The panel suggests AKT inhibitor trials in prostate cancer have been disappointing due to suboptimal biomarker selection (e.g., PTEN IHC). A similar drug in breast cancer showed significant survival benefit when using a more precise NGS-based strategy, indicating a potential path forward if the right patient population is identified genetically.

The CAPItello-281 trial showed that the clinical benefit of adding the AKT inhibitor capivasertib is directly proportional to the degree of PTEN loss. The greatest separation in survival curves was seen in patients with 99-100% PTEN loss by IHC, suggesting the current trial entry cutoff of >90% may be too broad for optimal patient selection.